|

Daratumumab SC Clinical Trials

2 actively recruiting trials across 2 locations

Pipeline

Phase 2: 2

Top Sponsors

  • National Cancer Institute (NCI)1
  • Carl Ola Landgren, MD, PhD1

Indications

  • Cancer2
  • Lymphoma, Primary Effusion1
  • Multiple Myeloma1

Miami, Florida1 trial

Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

University of Miami

Phase 2

Bethesda, Maryland1 trial

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

National Institutes of Health Clinical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.